G1 Therapeutics Inc   (GTHX)
Other Ticker:  
Price: $3.3200 $-0.01 -0.300%
Day's High: $3.56 Week Perf: 49.55 %
Day's Low: $ 3.20 30 Day Perf: -12.4 %
Volume (M): 1,716 52 Wk High: $ 5.00
Volume (M$): $ 5,697 52 Wk Avg: $2.46
Open: $3.20 52 Wk Low: $1.08

 Market Capitalization (Millions $) 171
 Shares Outstanding (Millions) 52
 Employees -
 Revenues (TTM) (Millions $) 83
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) -62
 Capital Exp. (TTM) (Millions $) 0

G1 Therapeutics Inc
G1 Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel targeted therapies for the treatment of cancer. The company specializes in developing small molecule inhibitors that selectively target specific proteins involved in cell cycle progression and DNA damage repair.

G1 Therapeutics aims to address the limitations of current cancer treatments by developing therapies that can improve outcomes for patients with a variety of cancer types. Their drug candidates are designed to target and modify the cell cycle, a critical process in the life cycle of a cell, to disrupt cancer cell growth and enhance the efficacy of existing cancer treatments.

The company's pipeline includes potential therapies for various solid tumors, including lung, breast, and pancreatic cancers. G1 Therapeutics focuses on both early-stage development to identify novel drug candidates and late-stage clinical trials to evaluate the safety and efficacy of these candidates.

Overall, G1 Therapeutics Inc is dedicated to advancing the field of oncology and providing innovative treatment options to cancer patients.

   Company Address: 700 Park Offices Drive Research Triangle Park 27709 NC
   Company Phone Number: 213-9835   Stock Exchange / Ticker: NASDAQ GTHX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

G1 Therapeutics Inc

Robust 45.102% Top-line rise at GTHX in the fiscal time-frame closing December 31 2023

In recent financial news, G1 Therapeutics Inc has reported its financial results for the fiscal year ending December 31, 2023. The company showcased a significant improvement in its financial performance compared to the previous year, with a decrease in loss per share and an increase in revenue.
For the fiscal year ending December 31, 2023, G1 Therapeutics Inc reported a decrease in loss per share of -$0.21 compared to the previous year's loss of -$0.73 per share. This indicates a positive trend in the company's financial position. Additionally, the company's earnings per share (EPS) improved from -$0.35 per share in the previous reporting season.

Clinical Study

Positive Interim Analysis Prompts Continuation of Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer: A Potential Breakthrough in Treatment

Published Mon, Feb 12 2024 9:06 PM UTC

aims to present the latest advancements in pharmaceutical research and development. This article provides an analysis of two recent articles on the continuation of the pivotal Phase 3 trial of Trilaciclib in treating metastatic triple negative breast cancer, following an interim analysis by an Independent Data Monitoring Committee (DMC).Summary of 1:The first article, G1 ...

Stock Market Announcement

G1 Therapeutics Enhances Talent Acquisition with Inducement Grants to Drive Innovation in Oncology

Published Fri, Dec 1 2023 9:28 PM UTC

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 - G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, has recently made an important announcement regarding the grant of inducement stock options and restricted stock units (RSUs) to a newly hired employee. This move is in li...

Clinical Study

Trilaciclib: Paving the Way for Improved Survival Outcomes in Metastatic Triple Negative Breast Cancer

Published Thu, Nov 30 2023 1:38 AM UTC

In a world where advancements in medical research are constantly underway, the fight against breast cancer has seen significant breakthroughs. Recently, G1 Therapeutics presented groundbreaking data at the 2023 San Antonio Breast Cancer Symposium (SABCS) that shed light on the long-term impact of trilaciclib on survival outcomes in patients with metastatic Triple N...

G1 Therapeutics Inc

G1 Therapeutics Inc Faces a Challenging Fiscal Period with a Loss of $-0.35 per Share

G1 Therapeutics Inc, a major pharmaceutical preparations company, has recently experienced significant fluctuations in its stock price and financial performance. Over the past five trading days, the company's stock gained an impressive 16.18%. However, compared to the previous year, the stock has gone down by a staggering 85.18%. Currently, G1 Therapeutics Inc stock is trading on the NASDAQ at a value 56.6% below its 52-week average.
The recent disappointing fiscal period announcement by G1 Therapeutics Inc shed light on the company's struggles. During this period, the company's revenue plummeted by 47.828% to $12.30 million. Moreover, G1 Therapeutics Inc posted a net deficit per share of $-0.35, as opposed to a deficit of $-0.59 in the same three months of the previous year. The earnings per share (EPS) also saw a decline from $0.14 per share, and the revenue tumbled by a significant 70.985% from $42.39 million.


G1 Therapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
G1 Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
G1 Therapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com